Drugs for Transposition of the Great Arteries (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 47)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Spironolactone |
Approved |
Phase 4 |
|
1952-01-7, 52-01-7 |
5833
|
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm Brand of Spironolactone
Alpharma Brand of Spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne Brand of Spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
ct-Arzneimittel Brand of Spironolactone
D00443
D013148
DB00421
Deverol
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona Alter
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
MLS002153245
MLS002207058
|
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
Novo Spiroton
Novopharm Brand of Spironolactone
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer Brand of Spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
Spiro L.U.T.
spiro von ct
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono Isis
Spironocompren
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Xenalon
ZINC03861599
|
|
2 |
|
Eplerenone |
Approved |
Phase 4 |
|
107724-20-9 |
443872
150310
|
Synonyms:
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
AC1L9FDC
AC-4213
C12512
CGP-30083
CHEBI:31547
CHEBI:726453
CHEMBL1095097
CID443872
D01115
Eplerenone
Eplerenone (JAN/USAN/INN)
|
Epoxymexrenone
Inspra
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
MolPort-003-986-216
NCGC00159559-01
NCGC00159559-02
S1707_Selleck
SC-66110
Selara
TL8000270
ZINC03985982
|
|
3 |
|
Mechlorethamine |
Approved, Investigational |
Phase 4 |
|
51-75-2 |
4033
|
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
|
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
NSC762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
β,β'-dichlorodiethyl-N-methylamine
|
|
4 |
|
diuretics |
|
Phase 4 |
|
|
|
5 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
6 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
7 |
|
Natriuretic Agents |
|
Phase 4 |
|
|
|
8 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
9 |
|
Hormones |
|
Phase 4 |
|
|
|
10 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
11 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4 |
|
|
|
12 |
|
Tadalafil |
Approved, Investigational |
Phase 3 |
|
171596-29-5 |
110635
|
Synonyms:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
Acdirca
ADCIRCA
C429886
CHEBI:41488
CHEMBL779
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
CID110635
CPD000466321
D02008
DB00820
FT-0080116
GF 196960
GF-196960
HMS2051N17
|
HSDB 7303
IC 351
Ic351
IC-351
ICOS 351
KS-1117
Lilly brand of tadalafil
LS-186558
LS-187015
LS-187770
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
|
|
13 |
|
Vasodilator Agents |
|
Phase 3,Phase 2 |
|
|
|
14 |
|
Phosphodiesterase Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
15 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 3 |
|
|
|
16 |
|
Acetylcysteine |
Approved, Investigational |
Phase 2 |
|
616-91-1 |
12035
|
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
L-acetylcysteine
|
L-Acetylcysteine
Lysox
L-α-acetamido-β-mercaptopropionic acid
Mercapturic acid
Mucolysin
Mucomyst
NAC
N-Acetyl-3-mercaptoalanine
N-acetylcysteine
N-Acetylcysteine
N-Acety-L-Cysteine
N-acetyl-L-(+)-cysteine
N-Acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
|
|
17 |
|
Simendan |
Investigational |
Phase 2 |
|
131741-08-7 |
|
18 |
|
Respiratory System Agents |
|
Phase 2 |
|
|
|
19 |
|
N-monoacetylcystine |
|
Phase 2 |
|
|
|
20 |
|
Dextrans |
|
Phase 2 |
|
|
|
21 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
22 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
23 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
24 |
|
Antidotes |
|
Phase 2 |
|
|
|
25 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
26 |
|
Plasma Substitutes |
|
Phase 2 |
|
|
|
27 |
|
Expectorants |
|
Phase 2 |
|
|
|
28 |
|
Protective Agents |
|
Phase 2 |
|
|
|
29 |
|
Antioxidants |
|
Phase 2 |
|
|
|
30 |
|
Blood Substitutes |
|
Phase 2 |
|
|
|
31 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
32 |
|
Hematinics |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Epoetin alfa |
|
Phase 1, Phase 2 |
|
113427-24-0 |
|
34 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 1 |
|
76631-46-4, 113775-47-6 |
5311068
56032
68602
|
Synonyms:
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexdor (T)
Dexmedetomidin
|
Dexmedetomidina
Dexmedetomidine
DEXMEDETOMIDINE
Dexmédétomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidinum
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
35 |
|
Adrenergic Agents |
|
Phase 1 |
|
|
|
36 |
|
Neurotransmitter Agents |
|
Phase 1 |
|
|
|
37 |
|
Analgesics |
|
Phase 1 |
|
|
|
38 |
|
Central Nervous System Depressants |
|
Phase 1 |
|
|
|
39 |
|
Adrenergic Agonists |
|
Phase 1 |
|
|
|
40 |
|
Adrenergic alpha-2 Receptor Agonists |
|
Phase 1 |
|
|
|
41 |
|
Adrenergic alpha-Agonists |
|
Phase 1 |
|
|
|
42 |
|
Analgesics, Non-Narcotic |
|
Phase 1 |
|
|
|
43 |
|
Peripheral Nervous System Agents |
|
Phase 1 |
|
|
|
44 |
|
Hypnotics and Sedatives |
|
Phase 1 |
|
|
|
45 |
|
Dobutamine |
Approved |
|
|
34368-04-2 |
36811
|
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
34368-04-2
34368-04-2 (Parent)
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
52663-81-7 (hydrochloride)
74753-15-4
74753-15-4 (hydrobromide)
AC1L1WFF
AC1Q7AD1
BPBio1_000489
BRD-A78322124-003-03-3
BSPBio_000443
C06967
CHEBI:4670
CHEMBL926
CID36811
D03879
DB00841
DL-dobutamine
DL-Dobutamine
Dobutamin
Dobutamina
Dobutamina [INN-Spanish]
dobutamine
Dobutamine
Dobutamine (USP/INN)
Dobutamine [Usan:Ban:Inn]
Dobutamine [USAN:BAN:INN]
|
Dobutamine [Usan]
Dobutamine [USAN]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine Hydrochloride
Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
dobutamine(usp)
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
EINECS 277-982-4
HMS2089K05
Inotrex
L001157
Lilly 81929
Lopac0_000365
LS-174467
LY 81929
NCGC00015321-05
NCGC00024629-02
NCGC00024629-03
Prestwick0_000352
Prestwick1_000352
Prestwick2_000352
Prestwick3_000352
rac-dobutamine
rac-Dobutamine
racemic-Dobutamine
Racemic-dobutamine
Racemic-Dobutamine
SPBio_002364
UNII-0WR771DJXV
UNII-3S12J47372
|
|
46 |
|
Adrenergic Antagonists |
|
|
|
|
|
47 |
|
Adrenergic beta-Antagonists |
|
|
|
|
|
Interventional clinical trials:
(show all 36)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Eplerenone in Systemic Right Ventricle |
Completed |
NCT00703352
|
Phase 4 |
Eplerenone |
2 |
The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease |
Terminated |
NCT01971593
|
Phase 4 |
Eplerenone |
3 |
Comparison of Hematocrit Levels in Infant Heart Surgery |
Completed |
NCT00006183
|
Phase 3 |
|
4 |
Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest |
Completed |
NCT00000470
|
Phase 3 |
|
5 |
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function |
Recruiting |
NCT03049540
|
Phase 3 |
Tadalafil 20 MG;Placebo 20 MG |
6 |
Levosimendan Administration in Neonates With Transposition of the Great Arteries |
Completed |
NCT01120106
|
Phase 2 |
levosimendan;placebo |
7 |
N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study) |
Completed |
NCT00374088
|
Phase 2 |
N-acetylcysteine;Placebo |
8 |
Hypertonic Saline Dextran in Pediatric Cardiac Surgery |
Completed |
NCT00199771
|
Phase 2 |
7.5% NaCl in 6% dextran 70 solution |
9 |
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery |
Active, not recruiting |
NCT00513240
|
Phase 1, Phase 2 |
Erythropoetin;Normal saline |
10 |
A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics |
Recruiting |
NCT01915277
|
Phase 1 |
Dexmedetomidine |
11 |
Cardiovascular MRI and Cardiopulmonary Exercise Capacity After Neonatal ASO) in Young Adults |
Unknown status |
NCT02415491
|
|
|
12 |
T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease |
Unknown status |
NCT02350829
|
|
|
13 |
MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries |
Completed |
NCT01916499
|
|
|
14 |
Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function |
Completed |
NCT00313352
|
|
|
15 |
Physical Training in Transposition of the Great Arteries |
Completed |
NCT00837603
|
|
|
16 |
CT Coronary Angiography After Arterial Switch Operation |
Completed |
NCT01153776
|
|
|
17 |
Right Ventricular Hypertrophy After Atrial Switch and Cardiovascular Magnetic Resonance (CMR) Findings |
Completed |
NCT01430897
|
|
|
18 |
Myocardial Contrast Echocardiography in Congenital Heart Disease |
Completed |
NCT00412685
|
|
|
19 |
Assessment of Left and Right Ventricular Function in Patients With Ebstein Anomaly With Different Echocardiographic Methods |
Completed |
NCT01907971
|
|
|
20 |
Quality of Life in Young Adults With Congenital Heart Disease |
Completed |
NCT02463292
|
|
|
21 |
Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome |
Completed |
NCT00713635
|
|
|
22 |
Reproduction and Survival After Cardiac Defect Repair |
Completed |
NCT00005190
|
|
|
23 |
Genes Causing Ebstein's Anomaly |
Completed |
NCT00497705
|
|
|
24 |
A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect |
Completed |
NCT02361008
|
|
|
25 |
Fibrosis, Valvular and Ventricular Function in Patients With TGA |
Recruiting |
NCT02588989
|
|
|
26 |
Genetic Determinants of Congenital Heart Disease Outcomes |
Recruiting |
NCT01656941
|
|
|
27 |
Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance |
Recruiting |
NCT02161471
|
|
|
28 |
The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease |
Recruiting |
NCT03073122
|
|
|
29 |
Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study) |
Recruiting |
NCT02184169
|
|
|
30 |
Comparative Assessment of Coronary MR Angiography Vs Coronary Multislice CT After Coronary Artery Reimplantation in Children and Young Adults. |
Recruiting |
NCT02542345
|
|
|
31 |
Assessing Neurodevelopment in Congenital Heart Disease. |
Recruiting |
NCT02996630
|
|
|
32 |
Xeltis Bioabsorbable Pulmonary Valved Conduit Early Feasibility Study |
Recruiting |
NCT03022708
|
|
|
33 |
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction |
Recruiting |
NCT02744677
|
|
|
34 |
Surgical Planning for Reconstruction of Complex Heart Defects |
Recruiting |
NCT00972608
|
|
|
35 |
Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction |
Active, not recruiting |
NCT02700100
|
|
|
36 |
Late Function After Surgery for Transposition of the Great Arteries |
Enrolling by invitation |
NCT03078413
|
|
|
|